Alnylam Pharmaceuticals EBIT 2010-2024 | ALNY

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Alnylam Pharmaceuticals 2023 EBIT was -0.282B, a 64.06% decline from 2022.
Alnylam Pharmaceuticals 2022 EBIT was -0.785B, a 10.78% increase from 2021.
Alnylam Pharmaceuticals 2021 EBIT was -0.709B, a 14.46% decline from 2020.

EBIT can be defined as earnings before interest and taxes.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Alnylam Pharmaceuticals 2023 EBIT was -0.282B, a 64.06% decline from 2022.
Alnylam Pharmaceuticals 2022 EBIT was -0.785B, a 10.78% increase from 2021.
Alnylam Pharmaceuticals 2021 EBIT was -0.709B, a 14.46% decline from 2020.

EBIT can be defined as earnings before interest and taxes.

Related Stocks
Company Name	Market Cap
Amgen (AMGN)	$173B
Vertex Pharmaceuticals (VRTX)	$129.4B
Gilead Sciences (GILD)	$121.9B
Bristol Myers Squibb (BMY)	$111B
CSL (CSLLY)	$91.9B
Regeneron Pharmaceuticals (REGN)	$90.6B
GSK (GSK)	$76B
Argenex SE (ARGX)	$35.4B
BioNTech SE (BNTX)	$25.7B
Biogen (BIIB)	$25.3B
Illumina (ILMN)	$24.6B
BeiGene (BGNE)	$20.1B
Moderna (MRNA)	$19.3B
Incyte (INCY)	$15.9B
Genmab (GMAB)	$15.3B
Insmed (INSM)	$12.8B
Vaxcyte (PCVX)	$12.8B
BioMarin Pharmaceutical (BMRN)	$12.8B
Bio-Techne Corp (TECH)	$12.1B
Sarepta Therapeutics (SRPT)	$11.5B
Exelixis (EXEL)	$10.2B
QIAGEN (QGEN)	$10.1B
Revolution Medicines (RVMD)	$9.9B
Exact Sciences (EXAS)	$9.9B
Intra-Cellular Therapies (ITCI)	$9.6B
Bio-Rad Laboratories (BIO.B)	$9.4B
Roivant Sciences (ROIV)	$8.7B
Repligen (RGEN)	$8.1B
Ascendis Pharma (ASND)	$7.7B
Viking Therapeutics (VKTX)	$7.7B